公开(公告)号：US20140288091A1

公开(公告)日：2014-09-25

申请号：US14350729

申请日：2012-10-10

申请人： ASTRAZENECA AB

发明人： Anna Minidis ,  Fredrik Rahm ,  Jenny Viklund

IPC分类号： C07D209/54 ,  A61K31/506 ,  A61K45/06 ,  A61K31/403 ,  A61K31/4439 ,  C07D491/107 ,  A61K31/407 ,  C07D403/04 ,  C07D401/04

CPC分类号： C07D209/54 ,  A61K31/403 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/506 ,  A61K45/06 ,  C07D207/34 ,  C07D401/04 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D491/107

摘要： Beta-secretase inhibitors, of formula (I) as described in the specification, pharmaceutical compositions comprising them and therapeutic methods using them for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

摘要翻译： 如说明书中所述的式（I）的β-分泌酶抑制剂，包含它们的药物组合物和使用它们用于治疗和/或预防与疾病相关的病症如唐氏综合征和淀粉样血管病变的治疗方法 但不限于脑淀粉样血管病或遗传性脑出血，与认知障碍相关的疾病，例如但不限于MCI（“轻度认知障碍”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病相关的神经变性 例如阿尔茨海默病或痴呆，包括混合血管和退行性起源的痴呆，老年痴呆，老年痴呆和与帕金森病相关的痴呆，进行性核上性麻痹或皮质基底变性。

公开(公告)号：US20100260765A1

公开(公告)日：2010-10-14

申请号：US12669724

申请日：2008-07-23

申请人： Simon Thomas Barry ,  Vahe Bedian ,  Bradley Hedberg ,  Jaspal Singh Kang ,  Qing Zhou

发明人： Simon Thomas Barry ,  Vahe Bedian ,  Bradley Hedberg ,  Jaspal Singh Kang ,  Qing Zhou

IPC分类号： A61K39/395 ,  C07K16/18 ,  C07H21/04 ,  C12N15/63 ,  C12N5/00 ,  A61P35/04

CPC分类号： C07K16/2863 ,  A61K38/16 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.

摘要翻译： 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地，本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。

公开(公告)号：US20050129774A1

公开(公告)日：2005-06-16

申请号：US10507368

申请日：2003-03-20

申请人： Sven Morein ,  Mats Berg ,  Christina Holmberg ,  Per Lundberg ,  Anders Ringberg

发明人： Sven Morein ,  Mats Berg ,  Christina Holmberg ,  Per Lundberg ,  Anders Ringberg

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/18 ,  A61K9/20 ,  A61K9/48 ,  A61K9/50 ,  A61K31/216 ,  A61K31/407 ,  A61K31/4184 ,  A61K31/4439 ,  A61K47/04 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61P1/04 ,  A61P25/00 ,  A61P25/04 ,  A61P29/00 ,  A61P43/00 ,  B01J2/00 ,  B01J2/20 ,  B01J2/22 ,  B01J20/04 ,  B01J20/24 ,  B01J20/28

CPC分类号： A61K9/5078 ,  A61K9/143 ,  A61K9/1611 ,  A61K9/1641 ,  A61K9/2072 ,  A61K9/2081 ,  A61K9/5026 ,  A61K31/407 ,  A61K31/4439

摘要： The present invention relates to porous particles comprising one or more NO-donating Non Steroidal Antiinflammatory Compound(s) optionally mixed with one or more surfactant(s) and to new solid drug delivery composition comprising said particles optionally in combination with a second active drug. Futhermore, the invention relates to processes for producing said porous particles and solid drug delivery composition as well as the use of said composition in the manufacturing of a medicament. The No-donating NSAID may be in oily or melted form.

摘要翻译： 本发明涉及包含任选与一种或多种表面活性剂混合的一种或多种供给NO的非甾体抗炎化合物的多孔颗粒和包含任选与第二活性药物组合的所述颗粒的新的固体药物递送组合物。 此外，本发明涉及生产所述多孔颗粒和固体药物递送组合物的方法以及所述组合物在制备药物中的用途。 不给予的NSAID可以是油性或熔化形式。

公开(公告)号：US20170313686A1

公开(公告)日：2017-11-02

申请号：US15516848

申请日：2015-10-07

申请人： AstraZeneca AB

发明人： Roland Bürli ,  Mark E. Duggan ,  Jörg Holenz ,  Patrik Johansson ,  Karin Kolmodin ,  Philip Vellacott Thorne ,  Michael John McKenzie

IPC分类号： C07D413/04 ,  C07D263/52 ,  C07D265/12

CPC分类号： C07D413/04 ,  A61K45/06 ,  C07B2200/05 ,  C07D263/52 ,  C07D263/62 ,  C07D265/12 ,  C07D413/10

摘要： The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

公开(公告)号：US09616028B2

公开(公告)日：2017-04-11

申请号：US14706077

申请日：2015-05-07

申请人： AstraZeneca AB ,  AstraZeneca UK Limited

发明人： Admassu Abebe ,  Kyle Martin ,  Jatin M. Patel ,  Divyakant Desai ,  Peter Timmins

IPC分类号： A61K9/28 ,  A61K9/24 ,  A61K31/155 ,  A61K31/7004 ,  A61K31/7042 ,  A61K45/06 ,  A61K31/403 ,  A61K31/70 ,  A61K31/7034 ,  A61K9/20

CPC分类号： A61K9/209 ,  A61K9/2054 ,  A61K9/282 ,  A61K31/155 ,  A61K31/403 ,  A61K31/70 ,  A61K31/7004 ,  A61K31/7034 ,  A61K31/7042 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

公开(公告)号：US20240360231A1

公开(公告)日：2024-10-31

申请号：US18589200

申请日：2024-02-27

申请人： AstraZeneca AB

发明人： Catharina LINDHOLM ,  Yen Lin CHIA ,  Rajendra TUMMALA ,  Lorin ROSKOS ,  Joachim ALMQUIST ,  Tomas ROUSE

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P37/06 ,  A61P43/00

CPC分类号： C07K16/2866 ,  A61P37/06 ,  A61P43/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

摘要： The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.

公开(公告)号：US12121517B2

公开(公告)日：2024-10-22

申请号：US18213601

申请日：2023-06-23

申请人： AstraZeneca AB

发明人： Peter Greasley ,  Christine Ahlström ,  Stanko Skrtic ,  Robert Menzies ,  Anne-Kristina Mercier ,  Mikael Sunnåker

IPC分类号： A61K31/497 ,  A61K31/7034 ,  A61P13/12

CPC分类号： A61K31/497 ,  A61K31/7034 ,  A61P13/12

摘要： The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

公开(公告)号：US20240325384A1

公开(公告)日：2024-10-03

申请号：US18618221

申请日：2024-03-27

申请人： AstraZeneca AB

发明人： Sabina Chiara COSULICH ,  Adam DOWSON ,  Jessica S. BROWN ,  Edit Eva LUKACS ,  Ganesh MOORTHY ,  Chris WILKS ,  Richard Edward FRANCIS

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61K9/28 ,  A61P35/00

CPC分类号： A61K31/496 ,  A61K9/0053 ,  A61K9/28 ,  A61P35/00

摘要： A method of treatment or prophylaxis of diseases or conditions in which inhibition of PARP1 is beneficial, comprising administering to the subject AZD5305 in a daily dose of 10 to 140 mg, wherein AZD5305 may be in the form of a pharmaceutically acceptable salt.

公开(公告)号：US20240316106A1

公开(公告)日：2024-09-26

申请号：US18583213

申请日：2024-02-21

申请人： AstraZeneca AB

发明人： Deepali Malhotra ,  Michael Overstreet ,  Gordon Moody ,  Mark Cobbold

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/05 ,  C07K14/47 ,  C07K14/82 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464452 ,  A61K39/464457 ,  A61K39/464464 ,  A61P35/00 ,  C07K14/05 ,  C07K14/4703 ,  C07K14/82 ,  C12N5/0636 ,  C12N9/22 ,  C12N15/111 ,  C12N15/86 ,  C12N2310/20 ,  C12N2740/15043

摘要： The disclosure relates to methods, cells, and compositions for preparing cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods for expansion and proliferation of primary immune cells including T cell populations.

公开(公告)号：US20240307383A1

公开(公告)日：2024-09-19

申请号：US18435463

申请日：2024-02-07

申请人： AstraZeneca AB

发明人： Philip Ambery ,  Peter Greasley ,  Anne-Kristina Mercier ,  Mikael Sunnåker

IPC分类号： A61K31/497 ,  A61K31/351 ,  A61P9/12

CPC分类号： A61K31/497 ,  A61K31/351 ,  A61P9/12

摘要： Methods for treating high proteinuria chronic kidney disease and/or at least one disease, disorder, or condition associated therewith in patients by the use of a fixed-dose combination of zibotentan and dapagliflozin are disclosed.